Elsevier

Brain Research

Volume 518, Issues 1–2, 4 June 1990, Pages 67-77
Brain Research

Histological and ultrastructural evidence thatd-amphetamine causes degeneration in neostriatum and frontal cortex of rats

https://doi.org/10.1016/0006-8993(90)90955-BGet rights and content

Abstract

d-Amphetamine sulfate, continuously administered for 3 days subcutaneously via an implanted minipump, induced neural degeneration in Long-Evans and Sprague-Dawley rats at doses between 20 and 60 mg/kg/day. Using Fink-Heimer silver staining, axonal degeneration was detected in the neostriatum and the dorsal agranular insular cortex and degenerating pyramidal cells were observed in portions of the somatosensory neocortex in both strains. In contrast, dense axonal degeneration largely confined to layers 2 and 3 of frontal motor areas (Fr1, Fr2 and Fr3 of Zilles36) with occasional degenerating cells was seen reliably in Long-Evans rats but rarely in Sprague-Dawley rats. In the electron microscope, cortical degeneration consisted mainly of disrupted cell bodies and dark processes, including axons making asymmetric synapses. Damage in all cortical areas represents damage to non-monoamine neurons and processes since tyrosine hydroxylase and serotonin immunolabeling were normal. In contrast, the damage in neostriatum probably includes damage to dopamine axonal terminals since tyrosine hydroxylase immunolabeling was patchy with many swollen and distorted labeled axons. Serotonin and Leu-enkephalin labeling were normal. Electron microscopy confirmed that the neostriatum contained many tyrosine hydroxylase-labeled axons that were swollen and disrupted, although other labeled processes made normal symmetric synapses onto spines and dendrites. Additional degeneration found only in amphetamine-treated rats included many dark, shrunken profiles. Some of these appeared to be astrocytic processes and a few were myelinated axons, suggesting that some non-monoamine, possibly cortical afferents, are also degenerating in the neostriatum. Since similar degrees of behavioral activation, weight loss and lethality were seen in both strains, a genetic predisposition constrain amphetamine-induced motor cortex damage but not neostriatal damage.

Reference (36)

  • RicaurteG.A. et al.

    Nerve terminal degeneration after a single injection ofd-amphetamine in iprindol-treated rats: relation to selective long-lasting dopamine depletion

    Brain Research

    (1984)
  • RicaurteG.A. et al.

    Further evidence that amphetamines produce long-lasting dopamine neurochemical deficits by destroying dopamine nerve fibers

    Brain Research

    (1984)
  • RyanL.J. et al.

    Continuous amphetamine induces tyrosine hydroxylase immunoreactive patches in the adult rat neostriatum

    Brain Res. Bull.

    (1988)
  • SeidenL.S. et al.

    Long-term methamphetamine-induced changes in brain catecholamines in tolerant rhesus monkeys

    Drug Alcohol Depend.

    (1976)
  • StoneD.M. et al.

    The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain

    Eur. J. Pharmacol.

    (1986)
  • WagnerG.C. et al.

    Long-lasting depletion of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine

    Brain Research

    (1980)
  • ComminsD.L. et al.

    Biochemical and histochemical evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain

    J. Pharmacol. Exp. Ther.

    (1987)
  • D'AmatoR.J. et al.

    Evidence for neuromelanin involvement in MPTP-induced neurotoxicity

    Nature (Lond.)

    (1987)
  • Cited by (108)

    • The Pathology of Methamphetamine Use in the Human Brain

      2013, The Effects of Drug Abuse on the Human Nervous System
    • The basal ganglia as a substrate for the multiple actions of amphetamines

      2011, Basal Ganglia
      Citation Excerpt :

      Continuous infusions of d-amphetamine via subcutaneous minipumps that deliver at least 20 mg/kg/day for 2 days produced axonal swelling and damage to TH positive terminals in the striatum. In addition, dark, shrunken profiles were observed in some glial processes, non-myelinated axons, and postsynaptic dendrites suggesting non-DAergic, terminal degeneration in the striatum [16,17]. Moreover, escalating doses of METH over a 1 month period have been shown to increase the number of mushroom and thin spines on MSN in the dorsolateral striatum, but decreased the number of mushroom spines in the dorsomedial striatum at 3 months after the drug treatment [18].

    View all citing articles on Scopus
    View full text